Pustular skin diseases reflect distinct innate defense pathways

Expert Review of Dermatology

Volumn 3, Issue 4, 2008, Pages 465-475

  Christophers, Enno ^a   Meyer, Thomas ^b  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Cutaneous defense circuit; IL 1; Innate immunity; Neutrophil; Pustule; Th17 cell

Indexed keywords

AMOXICILLIN; AMPICILLIN; C REACTIVE PROTEIN; CHLOROQUINE; CYTOKINE; DILTIAZEM; IMIQUIMOD; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 8; PRISTINAMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RETINOID DERIVATIVE; SULFONAMIDE; TERBINAFINE; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN RECOGNITION; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; BONE MARROW CELL; CELL INTERACTION; CELL MIGRATION; CYTOKINE RELEASE; DENDRITIC CELL; DRUG RECEPTOR BINDING; GRAM NEGATIVE BACTERIUM; HUMAN; IMMUNOPATHOGENESIS; INNATE IMMUNITY; KERATINOCYTE; LYMPHOCYTE ACTIVATION; MACROPHAGE; NEUTROPHIL; PRIORITY JOURNAL; PSORIASIS; PUSTULE; REVIEW; SIGNAL TRANSDUCTION; SKIN CELL; SKIN DEFECT; SKIN DISEASE; STAPHYLOCOCCUS AUREUS;

EID: 55449117279     PISSN: 17469872     EISSN: None     Source Type: Journal    
DOI: 10.1586/17469872.3.4.465     Document Type: Review

References (102)

1. Iwatsuki K, Yamasaki O, Morizane S, Oono T. Staphylococcal cutaneous infections: invasion, evasion and aggression. J. Dermatol. Sci. 42, 203-214 (2006).
2. Fox AB, Hambrick GW Jr. Recreationally associated Pseudomonas aeroginosa folliculitis. Arch. Dermatol. 120, 1304-1307 (1984).
3. Kluytmans J, van Belkum A, Verbrugh H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanism, and associated risks. Clin. Microbiol. Rev. 10, 505-520 (1997).
4. Medzhitov R, Janeway CA. Innate immunity. N. Engl. J. Med. 434, 338-344 (2000).
5. Foster TJ. Immune evasion by staphylococci. Nat. Rev. Microbiol. 3, 948-958 (2005).
6. Mertz PM, Cardenas TCP, Snyder RV, Kinney, MA, Davis SC, Plano LRW. Staphylococcus aureus virulence factors associated with infected skin lesions. Arch. Dermatol. 143, 1259-1263 (2007)
7. Fournier B, Philpott DJ. Recognition of Staphylococcus aureus by the innate immune system. Clin. Microbiol. Rev. 18, 521-540 (2005).
8. Hornung V, Rothenfusser S, Britsch S et al. Quantitative expression of Toll-like recepwr 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J. Immunol. 168, 4531-4537 (2002).
9. Peiser L, Mukhopadhyay S, Gordon S. Scavenger receptors in innate immunity. Curr. Opin. Immunol. 14, 123-128 (2002).
10. Carneiro LAM, Magalhaes JG, Tattoli I, Philpott DJ, Travassos LH. Nod-like proteins in inflammation and disease. J. Pathol. 214, 136-148 (2008).
11. Meylan E, Tschopp J, Karin M. Intracellular pattern recognition receptors in the host response. Nature 442, 39-44 (2006).
12. Bottazzi B, Garlanda C, Salvatori G, Jeannin P, Manfredi A, Mantovani A. Pentraxins as a key component of innate immunity. Curr. Opin. Immunol. 18, 10-15 (2006).
13. Eisen DP, Liley HG, Minchinton RM. Alternatives to conventional vaccines-mediators of innate immunity. Curr. Drug Targets 5, 89-105 (2004).
14. Imler JL, Hoffmann JA. Toll-like receptors in Drosophila: a family of molecules regulating development and immunity. Curr. Top. Microbiol. Imuunol. 270, 63-80 (2002).
15. O'Neill JA. Signal transduction pathwaysactivated by the IL-1 receptor/ Toll-like receptor superfamily. Curr. Top. Microbiol. Immunol. 270, 47-62 (2002).
16. Underhill DM. Toll-like receptors: networking for success. Eur. J. Immunol. 33, 1767-1775 (2003).
17. Hemmrich G, Miller DJ, Bosch TCG. The evolution of immunity: a low-life perspective. Trends Immunol. 28, 449-454 (2007).
18. Underhill DM, Ozinsky A. Toll-like receptors: key mediators of microbe detection. Curr. Opin. Immunol. 14, 103-110 (2002).
19. Travassos LH, Giardin SE, Philpott DJ et al. Toll-like receptor 2-dependent bacterial sensing does not occur via peptidoglycan recognition. EMBO Reports 5, 1000-1006 (2004).
20. Schröder JM, Harder J. Antimicrobial peptides and proteins. Cell. Mol. Life Sci. 63, 469-486 (2006).
21. Graham GM, Farrar MD, Crusc-Sawyer JE et al. Proinflammatory cytokine production by human keratinocytes stimulated with Propionibacterium acnes and P. acnes GroEL. Br. J. Dermatol. 150, 421-428 (2004).
22. Schaller M, Loewenstein M, Borelli C et al. Induction of a chemoattractive proinflammatory cytokine response after stimulation of keratinocytes with Propionibacterum acnes and coproporphyrin III. Br. J. Dermatol. 153, 66-71 (2005).
23. Mempel M, Voelcker V, Köllish G et al. Toll-like receptor expression in human keratinocytes: nuclear Factor ΚB controlled gene activation by Staphylococcus aureus is Toll-like eceptor 2 but not Toll-like. receptor 4 or platelet activating factor receptor dependent. J. Invest, Dermatol. 121, 1389-1396 (2003.)
24. Sasaki Kano R, Sato H. Nakamura Y, Watanabe S, Hasegawa A. Effects of staphylococci on cytokine production from human keratinocytes. Br. J. Dermatol. 148, 46-40 (2003)
25. Schröder JM, Gregory H, Young J, Christophers E. Neuthrophil-activating proteins in psoriasis. J. Invest. Dermatol. 98, 241-2417 (1992)
26. Schröder JM, Christophers E. The biology of NAP-1/IL-8 , a neuttrophil activating cytokine. Immunol. Ser. 57, 387-416 (1992)
27. Schröder JM, Christophers E. Identification of C5a des arg and anionic neutrophil-activating peptide (ANAP) in psoriatic scales. J. Invest. Dermatol. 87 53-58 (1986).
28. Fritz, JH, Le Bourhis L, Magalhaes JG, Philpott DJ. Innate immune recognition at the epithelial barrier drives adaptive. immunity: APCs take the back seat. Trends Immunol. 29, 41-49 (12008)
29. Fritz JH, Le Bourhis L, Sellge E et al. Nod1-mediated innate immune recognition of peptidoglycan contributes to the onset of adaptive immunity. Immunity 26, 445-459 (2007)
30. Camero AM, Oppenheim JJ. IL-1 can act as number one. Immunity 24, 16-17 (2006)
31. Miller LS. Pietras EM, Uricchio LH et al. Inflammation-mediated production of IL-1β is required for neutrophil recruitment against Staphylococcus aureus in vivo. J. Immunol 179, 6933-6942 (2007).
32. Matsukawa A, Yoshimura T. Maeda T, Takahashi T. Olikawara S, Yoshinaga M. Analysis of the cytokine network among tumor necrosis factor α, interleukin-1 β, interleukin-8, and interleukin-1 receptor antagonist in monosodium orace crystal-induced rabbit arthritis. Lab. Invest. 78, 559-569 (1998).
33. Matsukawa A. Yoshimura T, Fujiwara K, Maeda T, Ohkawara S, Yoshinaga M. Involvement of growth-related protein in lipopolysaccharide-induced rabbit arthritis: cooperation between growth-related, protein and IL8, and interrelated regulation among TNF-α, IL-1, IL-1 receptor antagonist, IL-8, and growth-related protein. Lab. Invest. 79, 591-600 (1999).
34. Miller LS, O'Connell R.M, Gutierrez MA et al. MyD88 mediates neutrophil recruitment initiated by IL-1R but not TLR2 activation in immunity againts Staphylococcus aureus. Immunity 24, 79-91 (2006)
35. + FXIIIA-macrophages. J. Clin. Invest. 117, 2517-2525 (2007).
36. Nickoloff BT, Karabin GD. Barker JN et al. Cellular localization of interleukin 8 and its inducer, tumor necrosis factor-α in psoriasis. Am. J. Pathol. 138, 129-140 (1991).
37. Sayers TJ, Wiltrout TA, Bull CA, Denn AC 3rd, Pilaro AM, Lokesh B. Effects of cytokines on polymorphonuclear neutrophil infiltration in the mouse: prostaglandine- and leukotriene-independent induction of infiltradon by IL-1 and tumor necrosis factor. J. Immunol. 141, 1670-1678 (1988).
38. Menegazzzi R, Cramer R, Patriarca P, Scheurich P, Dri P. Evidence that tumor necrosis factor α. (TNF)-induced activation of neutrophil respiratory burst on biologic surfaces is mediated by the p55 TNF receptor. Blood 84, 287-293 (1994).
39. Miskolci V, Rollins J, Vu HY, Ghosh CC, Davidson D, Vancurova I. NFκB is persisiently activated in continuously stimulated human neutrophils. Mol. Med. 13, 134-142 (2007).
40. Schmidt-Weber CB, Akdis M. Akdis CA. TH17 cells in the big picture of immunology. J. Allergy Clin. Immunol. 120, 247-254 (2007).
41. Wilson NJ, Boniface K, Chan JR et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat. Immunol. 8, 950-957 (2007).
42. Dragon S. Rahman MS, Yang J, Unruh H, Halayko AJ, Gounni AS. IL-17, enhances IL-1ß-mediated CXCL-8 release from human airway smooth muscle cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 292, 1023-1029 (1007).
43. Kolls JK, Linden A. Interleukin 17 family members and inflammation. Immunity 21, 467-476 (2004).
44. Ye P, Rodriguez FH, Kanaly S et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J. Exp. Med. 194, 519-527 (2001).
45. Huang W, NA L, Fidel PL, Schwarzenberger P. Requirement of interleukin-17 for systemic anti-Candida albicans host defense in mice. J. Infect. Dis. 190, 624-631 (2004).
46. Christophers E. Comorbidities in psoriasis. Clin. Dermatol. 25, 529-534 (2007).
47. Baker H, Ryan TJ. Generalizsed pustular psoriasis. A clinical and epidemiological study of 104 cases. Br. J. Dermatol. 80, 771-793 (1968).
48. Rocha-Pereira P, Santos-Silva A, Rebelo I et al. The inflammatory response in mild and severe psoriasis. Br. J. Dermatol. 150, 917-928 (2004).
49. Sergeant A, Makrygeorgou A, Chan WC, Thorrat A, Burden D. C-reactive protein in psoriasis. Br. J. Dermatol. 158, 417-419 (2008).
50. Beg AA. Endigenous ligands of Toll-like receptors: implications for regulating inflammatroy and immune responses. Trends Immunol. 23, 509-511 (2002).
51. Biragyn A, Ruffini PA, Leifer CA et al. Toll-like receptor 4-dependent activation of dendritic cells by β-defensin 2. Science 298, 1025-1029 (2002).
52. Lau CM, Broughton C, Tabor AS et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement, J. Exp. Med. 202, 1171-1177 (2005).
53. Lande R, Gregorio J, Facchinerti V et al. Plasmacytoid dendritic cells sense self-DNA. coupled with antimicrobial peptide. Nature 449, 564-569 (2007).
54. Korn T, Oukka M, Bettelli E, Th17 cells: effector T cells with inflammatory properties. Semin. Immunol. 19(6), 362-371 (2007)
55. Bettelli E, Korn T, Kuchroo VK. Th17: The third member of the effector T cell trilogy. Curr Opin. Immunol. 19, 652-657 (2007).
56. Hemmi H, Kaisho O, Takeucki S et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signalling pathway. Nat. Immunol. 3, 196-200 (2002).
57. Jurk M, Heil F, Vollmer J et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R848. Nat. Immunol. 3, 499 (2002).
58. Gilliet M, Conrad C, Geiges M et al. Psoriasis triggered by Toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch. Dermatol. 140, 1490-1495 (2004).
59. Rajan N, Langtry JA. Generalized exacerbation of psoriasis associated with imiquimod cream treatment of superficial basal cell carcinomas. Clin. Exp. Dermatol. 31, 140-141 (2006).
60. Farti PA, Dika E, Vaccari S, Miscial C, Varotti C. Generalized psoriasis induced by topical treatment of actinic keratosis with imiquimod. Int. J. Dermatol. 45, 1464-1465 (2006).
61. Means TK, Latz E, Hayashi F, Murali MR, Golenbock, DT, Luster AD, Human lupus autoantibody DNA complexes activate DCs Olrough cooperation of CD32 and TLR9. J. Clin. Invest. 115, 407-417 (2005).
62. Claudy A. Pathogenesis of leukocytoclastic vasculitis. Eur. J. Dermatol. 8, 75-79 (1998).
63. Nestle FO. Conrad C, Tun-Kyi A et al. Plasmacytoid predendritic cells (PDC) initiate psoriasis through IFN-α production. J. Exp. Med. 202, 135-143 (2005).
64. McKenzie BS, Kastelein RA, Cua DJ. Understanding the IL-23-IL17 immune pathway. Trends Immunol. 277, 17-23 (2006).
65. Langowski JL, Kastelein RA, Oft M. Swords into plowshares: IL-23 repurposes tumor immune surveillance. Trends Immunol. 28, 207-211 (2007
66. Iwakura Y, Ishigame H. The IL-23/IL-17 axis in inflammation. J. Clin. Invest. 116, 1218-1222 (2006).
67. Smits HH, van Beelen AJ, Hessle C et al. Commensal Gram-negative bacteria prime human dendritic cells for enhance IL-23 and IL-27 expression and enhanced Th1 development. Eur. J. Immunol. 34, 1371-1380 (2004).
68. Dong C. Diversification of T-helper cell lineages: finding the family root of IL-17-producing cells. Nat. Rev. Immunol. 6, 329-333 (2006).
69. Sa S, Valdez PA, Wu J et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggests potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J. Immunol. 78, 2229-2240 (2007).
70. Linden A. Laan M, Anderson GP. Neutrophils, interleukin-17A and lung disease. Eur. Respir. J. 25, 159-172 (2005).
71. Yao Z, Paintner SL, Fanslow WC et al. Human IL-17: a novel cytokine derived from T cells. J. Immunol. 155, 5483-5486 (1995).
72. Shen F, Hu Z, Goswami J, Gaffen SL. Identification of common transcriptional regulatory elements in interleukin-17 target genes. J. Biol. Chem. 281, 24138-24148 (2006).
73. Patel DN, King CA, Bailey SR et al. Interleukin-17 stimulates C-reactive protein expression in hepatocytes and smooth muscle cells via p38 MAPK and ERK1/2-dependent NFκB and C/EBPβ activation. J. Biol. Chem. 282, 27229-27238 (2007).
74. Takematsu H, Tagami H. Quantification of chemoractic peptides (C5a anaphylatoxin and IL8) in psoriatic lesional skin. Arch. Dermatol. 74-80 (1993).
75. Katz Y, Nadiv O, Rapoport MJ, Loos M. IL-17/regulates gene expression and protein synthesis of the complement system, C3 and factor B, in skin fibroblasts. Clin. Exp. Immunol. 120, 22-29 (2000).
76. Van de Kerkhof PC. Update on retinoid Therapy of psoriasis in: an update on the use of retinoids in dermatology. Dermatol. Ther. 19, 252-263 (2006).
77. Christophers E, Griffith CE, Gaitanis G, Van de Kerkhoff P. The unmet treatment need for moderate to severe psoriasis: results of a survey and chart view. J. Eur. Acad. Dermatol. Venereol. 20, 921-925 (2006).
78. Mucida D, Park Y, Turovskaya O, Scott I, Kronenberg M, Choutre H. Reciprocal Th17 and regulatory T cell differentiation mediated by retinoic acid. Science 317, 256-260 (2007).
79. Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Toxicology 209, 123-129 (2005).
80. Sidoroff A, Dunant A., Vibout C et al. Risk factors for acute generalized exanthematous pustulosis (AGEP) - results of a multinational case-control study (EuroSCAR). Br. J. Dermatol. 157, 989-996 (2007).
81. Takeuchi O, Akira S. Recognition of viruses by innate immunity. Immunol. Rev. 220, 214-224 (2007)
82. Wagner, H. The immunobiology of the TLR9 subfamily. Trends Immunol. 25, 381-386 (2004).
83. Johnson GB, Brunn GJ, Tang AH, Platt JL. Evolutionary clues to the functions of the Toll-like family as surveillance receptors. Trends Immunol. 24, 19-24 (2003).
84. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin-IgG-complexes activate B cells by dual engagement of IgM and Toll-like receptor. Nature 416, 60-607 (2002).
85. Lebre MC, van der Aar AMG, van Baarsen L et al. Human keratinocytes express functional Toll-like receptor 3, 4, 5, and 9. J. Invest. Dermatol. 127, 331-341 (2007).
86. Köllisch G, Kalali BN, Voelcker V et al. Various members of the Toll-like receptor family contribute to the innate immune response of human epidermal keratinocytes. Immunology 114, 531-541 (2005).
87. Nagase H, Okugawa S, Ota Y et al. Expression and function of Toll-like receptors in eosinophils: activation by Toll-like receptor 7 ligand. J. Immunol. 171, 3977-3982 (2003).
88. Hasan U, Chaffois C, Gaillard C et al. Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic cells, which activates gene transcription through MyD88. J. Immunol. 174, 2942-2950 (2005).
89. Gorden KB, Gorski KS, Gibson SJ et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J. Immunol. 174, 1259-1268 (2005).
90. O'Neill L. How Toll-like receptors signal: what we know and what we don't know. Curr. Opin. Immunol. 18, 3-9 (2006).
91. Jarrossay D, Napolitani G, Colonna M, Salusto F, Lanzavecchia A, Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur. J. Immunol. 31, 3388-3893 (2001)
92. Ito T, Amakawa R, Kaisho T et al. Interferon-α and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J. Exp. Med. 195, 1507-1112 (2002).
93. Krug A, Towarowski A, Britsch S et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with Cd40 ligand to induce high amounts of IL-12. Eur. J. Immunol. 31, 3026-3037 (2001).
94. Kadowaki N, Ho S, Antonenko R et al. Subsetes of human dendritic cell precursors express different Toll-like receptors and respond to different microbial antigens. J. Exp. Med.. 194, 863-869 (2001).
95. Martinon F, Tschopp J. NLR join TLRs as innate sensors of pathogens. Trends Immunol. 26, 447-454 (2005).
96. Uehara A, Fulimoto Y, Fukase K, Takada H. Various human epithelila cells express functional Toll-like receptors, NOD1 and NOD2, to produce antimicrobial peptides, but not proinflammatory cytokines. Mol. Immunol. 44, 3100-3111 (2007).
97. Gutierrez O. Pipaon C, Inohara N et al. Induction of Nod2 in myelomonocytic and intestinal epithelial cells via nuclear factor κB activation. J. Biol. Chem. 277, 41701-41705 (2002).
98. Beiter K, Wartha F, Albiger B et al. An endonuclease allows Streptococcus pneumoniae to escape from neutrophil extracellular traps. Curr. Biol. 16, 401-407 (2006).
99. Fritz JH, Giardin SE, Fitting C et al. Synergistic stimulation of human monocytes and dendritic cells by Toll-like receptor 4 and NOD1- and NOD2- activating agonists. Eur. J. Immunol.. 35, 2459-2470 (2005).
100. Tada H, Aiba S, Shibara K, Ohteki T, Takada H. Synergistic effect of Nod1 and Nod2 agonists with Toll-like receptor agonists on human dendritic cells to genereate interleukin-12 and T helper type 1 cells. Infect. Immun. 73, 7067-7976 2005).
101. Anders HJ. Innate pathogen recognition in the kidney: Toll-like receptors, NOD-like receptors, and RIG-like helicases. Kidney Int. 72, 1051-1056 (2007).
102. Kato H, Sato S, Yoneyama M et al. Cell type-specific involvement of RIG-I in antiviral response. Immunity 23, 19-28 (2005).